274 related articles for article (PubMed ID: 7011535)
1. Chemotherapy and immunotherapy of L1210 leukemic mice with antigenic tumor sublines.
Nicolin A; Canti G; Marelli O; Veronese F; Goldin A
Cancer Res; 1981 Apr; 41(4):1358-62. PubMed ID: 7011535
[TBL] [Abstract][Full Text] [Related]
2. In vitro generation of a highly immunogenic subline of L1210 leukemia following exposure to 5-(3,3'-dimethyl-1-triazeno)imidazole-4-carboxamide.
Contessa AR; Bonmassar A; Giampietri A; Circolo A; Goldin A; Fioretti MC
Cancer Res; 1981 Jun; 41(6):2476-82. PubMed ID: 7016315
[TBL] [Abstract][Full Text] [Related]
3. Drug-mediated increase of tumor immunogenicity in vivo for a new approach to experimental cancer immunotherapy.
Giampietri A; Bonmassar A; Puccetti P; Circolo A; Goldin A; Bonmassar E
Cancer Res; 1981 Feb; 41(2):681-7. PubMed ID: 7448813
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibodies to the L1210 murine leukemia cell line and to a drug-altered subline.
Testorelli C; Archetti YL; Aresca P; Del Vecchio L
Cancer Res; 1985 Nov; 45(11 Pt 1):5299-303. PubMed ID: 4053006
[TBL] [Abstract][Full Text] [Related]
5. Treatment of spontaneous leukemia in AKR mice with chemotherapy, immunotherapy, or interferon.
Bekesi JG; Roboz JP; Zimmerman E; Holland JF
Cancer Res; 1976 Feb; 36(2 pt 2):631-9. PubMed ID: 1082796
[TBL] [Abstract][Full Text] [Related]
6. In vitro lymphocyte stimulation and the generation of cytotoxic lymphocytes with drug-induced antigenic lymphomas.
Testorelli C; Franco P; Goldin A; Nicolin A
Cancer Res; 1978 Mar; 38(3):830-4. PubMed ID: 75062
[TBL] [Abstract][Full Text] [Related]
7. Increased immunogenicity of murine lymphoma cells following exposure to gamma rays in vivo.
Guadagni F; Roselli M; Fuggetta MP; Perno CF; Goldin A; Giuliani A
Chemioterapia; 1984 Dec; 3(6):358-64. PubMed ID: 6529777
[TBL] [Abstract][Full Text] [Related]
8. Drug-mediated immunogenic changes of virus-induced leukemia in vivo.
Houchens DP; Bonmassar E; Gaston MR; Kende M; Goldin A
Cancer Res; 1976 Apr; 36(4):1347-52. PubMed ID: 1260759
[TBL] [Abstract][Full Text] [Related]
9. L1210/DTIC antigenic subline: studies at the clone level.
Marelli O; Canti G; Franco P; Prandoni N; Ricci L; Nicolin A
Eur J Cancer Clin Oncol; 1986 Nov; 22(11):1401-5. PubMed ID: 2435557
[TBL] [Abstract][Full Text] [Related]
10. Response of drug-sensitive and -resistant L1210 leukemias to high-dose chemotherapy.
Griswold DP; Trader MW; Frei E; Peters WP; Wolpert MK; Laster WR
Cancer Res; 1987 May; 47(9):2323-7. PubMed ID: 3567926
[TBL] [Abstract][Full Text] [Related]
11. Effect of scheduling of combinations of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide and 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea on the Harding-Passey and Cloudman S91 mouse melanomas.
Hill HZ; Hill GJ
Cancer Res; 1982 Mar; 42(3):838-42. PubMed ID: 7059982
[TBL] [Abstract][Full Text] [Related]
12. Immunosensitivity and histocompatibility antigens in drug-altered leukemic cells.
Nicolin A; Franco P; Testorelli C; Goldin A
Cancer Res; 1976 Jan; 36(1):222-7. PubMed ID: 1248001
[TBL] [Abstract][Full Text] [Related]
13. Vaccination of leukemic mice with viable drug-altered leukemic cells.
Boerio D; Cavalli M; Marelli O; Veronese F; Nicolin A
Ric Clin Lab; 1978; 8(3):127-33. PubMed ID: 746293
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy immunogenicity.
Goldin A; Nicolin A; Bonmassar E
Recent Results Cancer Res; 1980; 75():185-94. PubMed ID: 7232831
[TBL] [Abstract][Full Text] [Related]
15. Participation of T-lymphocytes in the curative effect of a novel synthetic polyamine analogue, N,N'-bis[3-(ethylamino)propyl]-1,7-heptanediamine, against L1210 leukemia in vivo.
Bowlin TL; Prakash NJ; Edwards ML; Sjoerdsma A
Cancer Res; 1991 Jan; 51(1):62-6. PubMed ID: 1988107
[TBL] [Abstract][Full Text] [Related]
16. Adoptive immunity in mice challenged with L1210/DTIC clones.
Canti G; Ricci L; Marelli O; Franco P; Nicolin A
Cancer Immunol Immunother; 1987; 24(1):64-7. PubMed ID: 3545466
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacological alteration of the antigenic properties of experimental leukemias detected by lymphocyte transformation].
Testorelli C; Missiroli A; Di Padova F; Nicolin A
Boll Ist Sieroter Milan; 1976; 55(2):142-50. PubMed ID: 1023882
[TBL] [Abstract][Full Text] [Related]
18. Antimetastatic action and hematological toxicity of p-(3,3-dimethyl-1-triazeno)benzoic acid potassium salt and 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide used as prophylactic adjuvants to surgical tumor removal in mice bearing B16 melanoma.
Sava G; Giraldi T; Lassiani L; Nisi C
Cancer Res; 1984 Jan; 44(1):64-8. PubMed ID: 6690062
[TBL] [Abstract][Full Text] [Related]
19. Effect of 3-deazauridine on the metabolism, toxicity, and antitumor activity of azacitidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine.
Li ZR; Campbell J; Rustum YM
Cancer Treat Rep; 1983 Jun; 67(6):547-54. PubMed ID: 6190558
[TBL] [Abstract][Full Text] [Related]
20. Correlations between humoral immunity and successful chemotherapy-immunotherapy.
Cantrell JL; Killion JJ; Kollmorgen GM
Cancer Res; 1976 Sep; 36(9 pt.1):3051-7. PubMed ID: 788896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
